Kornimate/medical-research-clean huggingface dataset:
a novel combination oral agent to treat acne vulgaris

Conditions: ACNE VULGARIS

Summary: the purpose of this study is to evaluate a novel, combination product for the treatment of acne vulgaris in females


Eligibility criteria:
inclusion criteria: * healthy females 13 years of age or older * non-pregnant, non-lactating females * signed written informed consent form * must be able to understand and be willing to follow all study instructions * have a clinical diagnosis of acne vulgaris exclusion criteria: * female subjects who are pregnant or nursing * any concomitant dermatologic condition that may affect outcome measures * concurrent use of any other medication to treat acne vulgaris * have a history or clinical evidence of any other active acute or chronic medical disease or condition considered by the principal investigator as unsuitable for the study * are currently using any other investigational agent or device * have participated in any other clinical study within 90 days prior to enrollment * employees or family members of sponsor or research site
a single center diagnostic, cross-sectional study of coronary microvascular dysfunction

Conditions: Coronary Microvascular Disease; Ischemic Heart Disease; Myocardial Ischemia

Summary: among patients with stable ischemic heart disease who are referred for coronary angiography, a substantial proportion have non-obstructive coronary artery disease (cad). ischemia based on symptoms or stress testing may be due to coronary microvascular dysfunction in up to 40% of these patients. however, the mechanisms and optimal treatment of coronary microvascular dysfunction are unknown. aberrant platelet activity and inflammation have been hypothesized as mechanisms of microvascular dysfunction. investigators plan to evaluate association between platelet activity, inflammation, and coronary microvascular dysfunction in stable women referred for coronary angiography, and to identify non-invasive correlates of coronary microvascular dysfunction in these patients.

the objectives of this study are to 1. investigate platelet activity and inflammation in patients with and without coronary microvascular disease who are referred for coronary angiography for the evaluation of stable ischemic heart disease and are found to have non-obstructuve epicardial cad 2. to identify correlates of coronary microvascular dysfunction in non coronary microvascular beds that can be characterized in vivo.

Eligibility criteria:
inclusion criteria: * adult women age ≥18 years referred for coronary angiography * stable ischemic heart disease, defined by ischemic symptoms and/or myocardial ischemia by stress testing * administration of aspirin therapy prior to cardiac catheterization exclusion criteria: pre-cath exclusion criteria: * active bleeding and/or bleeding diathesis * anemia (hemoglobin \<9 mg/dl) * known thrombocytosis (platelet count \>500,000) * know thrombocytopenia (platelet count \<100,000) * nsaids (e.g., ibuprofen, naproxen) within 3 days * platelet antagonists other than aspirin and thienopyridines, within 7 days * prior percutaneous coronary intervention or coronary artery bypass grafting * acute myocardial infarction within 3 months * severe valvular heart disease * cardiogenic shock or mechanical circulatory support * new york heart association (nyha) functional class iii or iv heart failure * ejection fraction \<40% * hypertrophic obstructive cardiomyopathy or severe left ventricular hypertrophy * pregnancy * contraindication to intravenous infusion of adenosine during coronary angiography, due to known hypersensitivity to adenosine, known or suspected bronchoconstrictive or bronchospastic lung disease (severe asthma), second- or third-degree av block (except in patients with a functioning artificial pacemaker), or sinus node disease, such as sick sinus syndrome or symptomatic bradycardia, angiographic exclusion criteria: * obstructive cad (≥50% luminal obstruction in ≥1 major epicardial coronary arteries by invasive coronary angiography) * unfavorable coronary artery anatomy for guidewire positioning (as determined by the angiographer or pi)
drug-disease interaction in crohn's disease

Conditions: Crohn's Disease

Summary: objective: to determine the effect of c-reactive protein (crp) status, and infliximab treatment on the pharmacodynamics and pharmacokinetics of verapamil, a model drug for l-type calcium channel blocking, in crohn's disease (cd) patients compared to healthy patients. hypotheses:cd patients will have elevated plasma verapamil concentrations, but diminished dromotropic response to verapamil; the concentration of circulating norepinephrine, used as a surrogate marker of sympathetic nervous activity, will be similar between the healthy patients and the cd patients; the sympathetic nervous system of the heart will be similar to healthy patients; crohn's disease patients with normal crp will have higher drug response compared to high crp (\>3 mg/l) patients; and that infliximab-treated patients will have higher verapamil response than those with similar symptom profiles who are not infliximab treated.


Eligibility criteria:
inclusion criteria: * willingness to adhere the study protocol * males of females of non-childbearing potential aged from 18 to 65 years * lab values no more than 10% outside of the lab's stated normal range unless the subject is in the crohn's disease group and the values are related to the disease, or if the pi decides the abnormality is not clinically significant * the subject is healthy (except for the crohn's disease group) * non-smoker for at least 3 months exclusion criteria: * history of hypersensitivity to verapamil * significant history of gastrointestinal (other than crohn's disease), liver, kidney, or any other disease or condition known to interfere with the absorption, distribution, metabolism or excretion of drugs * significant history of allergies * significant history of cardiovascular or hematological disease * significant history of asthma, chronic bronchitis or bronchospastic conditions * presence of diabetes mellitus or any other condition which would preclude fasting * maintenance therapy with any drug (except those prescribed for crohn's disease) or a history of drug dependence, alcohol abuse, or serious psychological disease * any clinically significant illness other than crohn's disease in the previous 30 days prior to the study * use of enzyme-modifying drugs in the previous 30 days before the study * blood donation in the previous 56 days or multiple blood samplings in the previous 30 days before the study * history of fainting upon blood sampling * participation in another clinical trial within 30 days of the study * narcotic use * glucocorticoid treatment in the last 30 days

Keywords: inflammation receptor downregulation reduced response calcium channels pk-pd relationship
syndemics and loss from the hiv care continuum in india - intervention

Conditions: HIV Infections

Summary: the investigators will assess the feasibility and acceptability of a pilot intervention to keep people living with hiv (plhiv) in southern india in care and virologically suppressed. the lack of understanding of the causes of loss from the hiv care continuum in india stifles the armamentarium of effective interventions to keep indian plhiv in care. the results of this research will demonstrate the feasibility and acceptability of a pilot intervention targeting the multiple mechanisms by which plhiv become lost to care. by targeting these mechanisms, this intervention will be designed to be scalable in a setting where access to mental health specialists is limited.

this pilot intervention represents the final aim of the nimh-sponsored study "syndemics and loss from the hiv care continuum in india." this trial will be conducted at the y.r. gaitonde centre for aids research and education (yrg care), located in chennai, the capital of tamil nadu state and one of the epicenters of the indian hiv epidemic. the investigators will recruit 50 adult (age \>=18) plhiv presenting to care at yrg care and art-naïve. participants will be recruited at their first visit to yrg care, at which the participant's hiv diagnosis is established or confirmed and the participant receives initial counseling and clinical care. at this recruitment stage, research assistants will conduct a pre-intervention questionnaire including measures of depressive symptoms, internalized stigma, self-efficacy, mental health, and physical health. the investigators will then randomize the patient to usual care vs. enhanced-care intervention (25 in each arm). the enhanced-care intervention will be multi-faceted, reflecting the likelihood of multiple syndemic conditions as well as evidence from lmics suggesting that programs combining multiple approaches are the most effective in improving retention in care. the enhanced-care intervention will consist of the following components: 1. active outreach, including bidirectional weekly sms messaging / automated voice messaging (depending on literacy) 2. appointments (specific appointment times/dates). 3. financial support, including free clinic visits, labs, medications, and transportation incentives on a sliding scale based on distance to clinic 4. microenterprise, including bag-making or food-making ventures for women 5. enhanced counseling. participants in the enhanced-care intervention will participate in an individual enhanced counseling program called steps to success, based upon a life steps and problem solving curriculum.

Eligibility criteria:
inclusion criteria: * adult plhiv presenting to care at yrg care who are art-naïve and who plan to follow-up at yrg care * speaks tamil, telugu, or english exclusion criteria: * previous art exposure * not competent to provide informed consent or participate in the study

Keywords: hiv india retention continuum
comparison of triphasic ct, pet and mr tumour with pathological findings in colorectal cancer liver metastases

Conditions: Liver Metastases; Colorectal Cancer

Summary: the purpose of this study is to correlate the mri ct and pet appearances of colorectal liver metastases to pathologic appearance ot better understand the accuracy of imaging to determine tumor size.

the purpose of this study is to correlate the mri ct and pet appearances of colorectal liver metastases to pathologic appearance ot better understand the accuracy of imaging to determine tumor size.

Eligibility criteria:
inclusion criteria: * liver metastases from colorectal cancer undergoing liver resection exclusion criteria: * contraindication to ct, mri or pet
metformin induces a dietary restriction-like state in human

Conditions: Overweight Subjects; Metformin; Aging

Summary: the fact that metformin treatment has been associated with reduced risk of cancer and cardiovascular disease raises the possibility of a beneficial role of metformin for other age-related diseases. the actions of metformin resemble the effects of calorie restriction (cr) to some extent, and microarray analyses have shown that metformin induces a gene expression profile that aligns with that of cr in animal. the aim of the study is to investigate whether metformin treatment can induce dietary restriction-like state in human. sixty overweight subjects will be included in this study, and participants will be divided 3 groups (20 cases in each group)including metformin group (0.85, twice daily), standard diet group, and cr group. all subjects will be treated 6 months. at the end of this study, blood samples and muscle samples will be obtained.

blood samples will be obtained from all individuals. blood lipids, inflammation markers, insulin, glucose, leptin,adiponectin, ala aminotransferase, asp aminotransferase, creatine phosphokinase,lactate dehydrogenase, alkaline phosphatase,bilirubin, cyclo-oxygenase, citrate synthase, renal function, leukocyte telomere length ratio, and telomerase activity will be measured before and after the treatments.also, hyperinsulinemic-euglycemic clamp will be performed before and after the treatments. muscle samples will be obtained by biopsy for 9 individuals (3 cases from each group) at the end of the study. microarray analysis will be performed for the gene expression profile from the muscle samples. other protein expressions such asadenosine monophosphate-activated protein kinase (ampk), peroxisome proliferator-activated receptor coactivator 1a (pgc-1a) activity,will be checked by western blot.

Eligibility criteria:
inclusion criteria: * overweight * male exclusion criteria: * female * obesity * using any other drugs * \< 18 years old * \> 60 years old * mental disorders * surgery history for abdomen
hemostasis in open acetabulum and pelvic ring surgery using tranexamic acid

Conditions: Acetabulum Fractures

Summary: this study is investigating the use of tranexamic acid (txa) in patients with pelvis and/or hip socket fractures that require surgery. txa is fda-approved in patients with hemophilia for short-term use to reduce hemorrhage and the need for replacement blood during tooth extraction. however, it has also been used extensively in severely injured patients after major trauma and during elective hip and knee replacements. previous studies indicate txa may reduce blood loss and the need for blood transfusions while being safe for use in most patients. txa is fairly inexpensive and easy to obtain. the purpose of this study is to determine if txa will make surgery in patients with pelvis and/or hip socket fractures safer and more cost efficient.

study candidates will be identified as they present to the university hospital emergency room and will be recruited for enrollment. randomization will occur by electronic randomization software. prior to surgery, the pharmacy will be notified of an enrolled patient and will be responsible for randomization and creating either a placebo intravenous dose or a treatment study dose. both study groups will receive the standard of care treatment for intra-operative hemorrhage control.

Eligibility criteria:
inclusion criteria: * adult patients (18 years of age or greater) with acetabulum fractures and/or pelvic ring injuries that require operative fixation via an open surgical approach exclusion criteria: * revision surgery * surgery occurring more than 2 weeks post-injury * history of blood dyscrasia or renal insufficiency * history of any thromboembolic disease * pregnancy or nursing, color vision defects * history of retinal detachment/degeneration * intracranial hemorrhage * hypersensitivity to tranexamic acid * contraceptive use (estrogens/progestins) * feiba (anti-inhibitor coagulant complex) use

Keywords: acetabulum fractures pelvic ring injuries tranexamic acid
bicentric study on the use of ecmo-vv or va for severe ards associated with covid-19

Conditions: Covid-19

Summary: describes the cohort of patients receiving ecmo-vv or ecmo-va in the management of severe ards refractory to sars-cov-2 in the strasbourg and louvain centres


Eligibility criteria:
inclusion criteria: * patient over the age of 18; * diagnostic covid-19 by rt-pcr; * hospitalisation in resuscitation for the management of complications related to covid-19 * implanted ecmo-vv or va during hospitalisation; * patient agreeing to participate in the study exclusion criteria: * sujet who has expressed opposition to participating in the study. * sujet under guardianship or trusteeship * sujet under safeguard of justice

Keywords: respiratory distress syndrome sars-cov-2 extracorporeal membrane oxygenation ecmo-vv ecmo-va veno-venous ecmo
pilot trial of novel circumcision device

Conditions: Safe Circumcision

Summary: the investigators are testing a novel surgical device to facilitate safe circumcision among adult males. the investigators hypothesize that this device will allow non-medical providers to perform safe surgical circumcision without adverse events.

objective: to conduct a proof-of-concept study to determine the potential utility of a novel, adjustable single-visit, disposable device to facilitate rapid adult circumcision. design: prospective pilot trial of a novel surgical device setting: tertiary care veterans administration medical center patients: 5 adult males interventions: circumcisions performed by junior trainees using an adjustable, single-size surgical-assist device constructed by the university of washington applied physics laboratory. main outcome measure(s): the attending surgeon and trainees completed standardized forms after each procedure to assess technical problems and ease of use. follow-up visits were scheduled to evaluate adverse events, post-operative pain, cosmetic outcomes and participant satisfaction at 3, 8, 30 and 90 days post-operatively.

Eligibility criteria:
inclusion 1. uncircumcised males 2. aged\>18 3. sexually active 4. no plans for moving in next 6 months 5. consent to participate exclusion 1. history of a bleeding disorder 2. history of a documented concurrent sti of appearance of an sti on initial physical exam 3. keloid formation or other condition that might unduly increase risk of elective surgery 4. asprin, anti-coagulants or other clinical contra-indications

Keywords: circumcision hiv prevention
effects of antioxidant supplementation of culture media on ivf embryos

Conditions: Infertility, Female; Infertility, Male

Summary: the goal of this clinical trial is to investigate the impact of repeated antioxidant supplementation on blastocyst utilization and expansion rates in embryos under different oxygen concentrations. the study aims to answer the following main questions: * does adding antioxidants every 12 hours to embryo culture media improve usable and expanded blastocyst utilization rates on days 5 and 6? * how are the o2 concentrations related to the effect of different methods of antioxidants supplementation on blastocysts utilization and expansion rates? participants in this study are infertile couples undergoing in vitro fertilization (ivf) or intracytoplasmic sperm injection (icsi) cycles. * zygotes will be incubated at either 5% or 20% oxygen tension until the blastocyst stage. * sibling zygotes will be divided into four groups: group 1a and 1b: antioxidants every 12 hours at either 5% or 20% o2 tension, respectively. group 2a and 2b: antioxidants only once at the beginning of embryo culture at either 5% or 20% o2 tension, respectively. researchers will compare the four groups to determine if the repeated antioxidant supplementation of the culture media leads to improved blastocyst utilization and expansion rates compared to the baseline group.

this study is focused on the role of antioxidants (aoxs) in mitigating reactive oxygen species and oxidative stress, which have been associated with failure in in vitro fertilization (ivf) and intracytoplasmic sperm injection (icsi). the research aimed to evaluate the effect of two different methods of antioxidants supplementation at two o2 tensions on blastocyst utilization and expansion rates. to achieve this, 3603 zygotes from infertile couples undergoing ivf or icsi were included in the study. the zygotes were divided into two groups: group 1a and 1b: antioxidants every 12 hours at either 5% or 20% o2 tension, respectively. group 2a and 2b: antioxidants only once at the beginning of embryo culture at either 5% or 20% o2 tension, respectively. .

Eligibility criteria:
inclusion criteria: * infertile women with from 18 to 37 years old at the moment of oocyte collection, tubal factor, polycystic ovary syndrome, uterine factor, or unexplained infertility. * more than 2 oocytes by conventional in vitro fertilization (civf) and intracytoplasmic sperm injection (icsi). exclusion criteria: * infertile woman in assisted reproduction treatment with less than 2 oocytes collected. * infertile woman in assisted reproduction treatment with less than 2 oocytes fertilized by conventional in vitro fertilization (civf) and intracytoplasmic sperm injection (icsi)

Keywords: blastocyst rate ivf embryo culture antioxidants
impact of gse and xylitol (xlear) on covid-19 symptoms and time to pcr negativisation in covid-19 patients

Conditions: Covid19

Summary: this clinical trial aims to ascertain the impact of gse and xylitol (xlear) in decreasing the time of negativisation in pcr testing in patients with covid-19.


Eligibility criteria:
inclusion criteria * adults of ages 18 to 90 years of both sexes * with positive sars-cov-2 carriage confirmed by nasopharyngeal pcr * signed informed consent * 1- mild symptoms: minimum respiratory symptoms or asymptomatic plus positive test * 2- moderate symptoms: respiratory symptoms such as cough, mild shortness of breath with mild oxygen desaturation(room air spo2 \ 88% or \ 92% with 2lt of oxygen) exclusion criteria * patients with severe symptoms: hypoxia (spo2 \<88% not corrected by 2 lt nc oxygen) plus severe shortness of breath (excluded) * patient with very low viral load (threshold cycle \[ct\] \> 25 per pcr). * known hypersensitivity to one of the constituents, particularly to xylitol or gse * under 18 years of age * women of childbearing age who are pregnant, breastfeeding mothers, and intend to become pregnant during the study period; unwilling/unable to take a pregnancy test. * unable to provide informed consent or decline to consent or unwillingness to adhere to the standard of care protocol. * patients with severe symptoms -hypoxia (spo2 \<88% not corrected by 2 liter non- concentrated oxygen) plus severe shortness of breath * history of immunodeficiency or are currently receiving immunosuppressive therapy. * have had a planned surgical procedure within the past 12 weeks. * already part of this trial, recruited at a different hospital. * patient unable to perform oro-nasopharyngeal decolonization * patients with acute exacerbation of severe comorbidities like heart disorders chronic obstructive pulmonary disease (copd), heart failure new york heart association (nyha) class 3 and 4 and/or diseases with severe oxygenation problems * patients on remdesivir and/or other clinical trials.

Keywords: intranasal spray covid19